Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Infants with B-cell acute lymphoblastic leukemia (B-ALL), especially those with relapsed or refractory disease, historically have significantly worse outcomes compared with older children with B-ALL. Investigators evaluated the experiences of 19 infants with relapsed/refractory B-ALL from three clinical trials that evaluated experimental CD19 CAR T-cell products in this patient population. They found that the clinical outcomes for the patients in this group were encouraging compared to historic controls, warranting future research into CAR T-cell therapy for this patient group.